News
Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...
Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...
GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment
GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for ...
3d
Zacks Investment Research on MSNMDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing RightsMadrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark ...
Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results